In February 2014, the U.S. Food and Drug Administration's (FDA's) Cellular, Tissue, and Gene Therapies Advisory Committee met to consider the possibility of future clinical trials that would test mitochondrial manipulation technologies for two purposes: to treat infertility and to prevent the transmission of mitochondrial disease from women to their future children. This meeting focused on scientific, technological, and clinical issues. The FDA acknowledged “ethical and social policy issues related to genetic modification of eggs and embryos” but chose not to engage with them, at least not yet (1). Good ethics begins with good facts, but the effort by the FDA to get the facts straight is just the beginning, not the end, of the conversation we must have on the wisdom of mitochondrial manipulation and other reproductive technologies that potentially provide parents with more of a say about the children they have. Preventing a lethal disease is one thing; choosing the traits we desire is quite another.
A Mexican standoff with the United States turned into a Mexican smack-down this month with the release of Mexico’s formal rebuttal to US efforts to overturn limits Mexico has ordered on the use of genetically modified (GM) corn and the...
The U.S. government must move “quickly and decisively” to avert substantial national security risks stemming from artificial intelligence (AI) which could, in the worst case, cause an “extinction-level threat to the human species,” says a report commissioned by the U.S...
By Nada Hassanein, New Jersey Monitor | 03.14.2024
Aggregated News
The U.S. Food and Drug Administration late last year approved two breakthrough gene therapies for sickle cell disease patients. Now a new federal program seeks to make these life-changing treatments available to patients with low incomes — and it could...
The Center for Genetics and Society is fiscally sponsored by Tides Center, a 501(c)(3) non-profit organization.
Please visit www.tides.org/state-nonprofit-disclosures for additional information.
